Online inquiry

IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1499MR)

This product GTTS-WQ1499MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1499MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13040MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ8498MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ6919MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ9465MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ12422MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ8250MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ13846MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ7447MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GBR500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW